Zinc modulates c-Myc/Mad1 balance in human leukemia cells
is an essential component in the diet of mammals, and its deficiency has been associated with enhanced susceptibility to cancer. 1 Zn ++ is found in more than 300 metalloenzymes, influencing gene expression by either structural stabilization or functional regulation of various transcription factors. However, the role of this metal ion in tumor development has not been yet elucidated.
We report here that addition of 100 M ZnSO 4 to cultures drastically inhibited c-Myc protein expression in different types of human leukemia cells, and that its activity was concentration-dependent (Figures 1a and 2a) . The inhibitory effect of Zn ++ on c-myc expression was not related to a pro-apoptotic effect, since the percentage of apoptotic cells as assessed by AnnexinV-FITC cell binding did not change in ZnSO 4 -treated cells, being Ͻ6% of total cells up to 24 h of treatment (data not shown). In contrast, the expression of either structurally or functionally related proteins Max and Tal-1 was not affected (Figure  2b and c) . Interestingly, we observed that Zn ++ reduced c-Myc protein levels also in Burkitt's lymphoma cells (Raji cell line). In these cells, c-Myc expression is increased in basal conditions as a consequence of a deregulated rate of transcription, but this effect was not present in VLL lymphoblastoid B line, where c-Myc enhanced expression is mainly due to increased mRNA stability (Figure 2d) . 2 Further study is needed to clarify this issue.
These findings were firstly observed using the Zn ++ sulfate salt. To extend our results to other Zn ++ salts, additional experiments were performed using zinc acetate ((CH 3 COO) 2 Zn) and zinc chloride (ZnCl 2 ). Both these zinc salts also elicited a significant inhibition of c-myc expression (Figure 1b c-Myc is a transcription factor that plays a pivotal role in the regulation of cell growth, cell-cycle progression, apoptosis and terminal differentiation. 3 Therefore, perturbation of c-Myc levels is critical in influencing growth of malignant cells, and in particular in those of . c-Myc expression was maximally suppressed at 6 h, and returned to basal levels 24 h after treatment (Figure 3a) . A parallel up-regulation of c-Myc antagonist Mad1 expression was observed, reaching its highest level 6-8 h after Zn ++ treatment, in correspondence with the nadir of c-myc expression (Figure 3b ).
To determine at what level Zn ++ suppresses c-Myc expression, we analyzed c-myc mRNA expression in HL-60 cells treated or not with 100 M ZnSO 4 . Our results revealed that Zn ++ induced a marked decrease in c-myc mRNA levels within 3 h after treatment (Figure 3c ). The early down-regulation of c-myc mRNA, as well as of c-Myc protein, is in accordance with the notion that they both have naturally short lives. 4 Analysis of mad1 mRNA level revealed a progressive increase starting from 3 h and reaching a maximum point 6 h after incubation with Zn ++ , closely paralleling c-myc suppression ( Figure  3d) .
Consistent with its normal role in promoting cell growth, c-Myc is frequently over-expressed in human neoplasms and can also drive oncogenic transformation. In particular, c-myc gene has been frequently found to be rearranged and its expression deregulated in a wide range of tumors, including hematological malignancies. 5 The ability of Zn ++ to suppress c-Myc expression suggests a possible role for this metal in the modulation of c-Myc-induced oncogenic transformation. In this regard, inactivation of Myc expression was found to induce tumor regression of malignant lymphoid and myeloid leukemia in a transgenic mouse model. 6 Furthermore, Zn ++ administration was shown to inhibit carcinogenesis in some animal tumor models. 8 Our finding that Mad1 was up-regulated concomitantly with c-Myc suppression, demonstrates that Zn ++ critically interferes in the balance between these two mutually regulated proteins.
In conclusion, the data presented here provide new insights for the use of Zn ++ as a regulator of cell growth by interference with cMyc/Mad1 balance possibly when used at over physiological concentration. This suggests that Zn ++ might represent a potential therapeutic tool against cancer, possibly in combination with other anti-tumor agents. We believe that the effects of this metal ion on cancer-related genes deserve further investigation.
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